


240/090
PATENT

CLAIMS

WHAT IS CLAIMED:

- 5 1. A pyrrole substituted 2-indolinone having the chemical structure:



wherein:

- 10 R¹ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, acetyl, C-amido, C-thioamido, sulfonyl and trihalomethanesulfonyl;
- R² is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl and heteroalicyclic;
- 15 R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl,
- 20 C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-

240/090
PATENT

carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and -NR¹¹R¹²;

R¹¹ and R¹² are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring;

R³ and R⁴, R⁴ and R⁵, or R⁴ and R⁵ may combine to form a six-member aryl ring, a methylenedioxy group or an ethylenedioxy group;

R⁷ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethanesulfonyl;

R⁸, R⁹ and R¹⁰ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, carbonyl, C-carboxy, O-carboxy, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and -NR¹¹R¹², providing, however, that at least one of R⁸, R⁹ or R¹⁰ is a group having the formula -(alk)₁Z wherein:

Alk₁ is selected from the group consisting of alkyl, alkenyl or alkynyl; and,
Z is a polar group.

2. The compound of claim 1 wherein R¹ R² and R⁷ are hydrogen.

3. The compound of claim 2 wherein one of R⁸, R⁹ or R¹⁰ is alk₁Z wherein:

240/090
PATENT

alk₁ is selected from the group consisting of unsubstituted lower alkyl, unsubstituted lower alkenyl and unsubstituted lower alkynyl; and,

Z is a polar group selected from the group consisting of hydroxy, alkoxy, C-carboxy, carbonyl, nitro, cyano, amino, ammonium, -NR¹¹R¹², C-amido, S-sulfonamido, sulfinyl, sulfonyl, phosphonyl, ureido, amidino, guanidiny, morpholino, piperidiny and tetrazolo.

- 10 4. The compound of claim 1 wherein wherein R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of:
hydrogen;
halo;
unsubstituted lower alkyl;
15 lower alkyl substituted with one or more groups selected from the group consisting of:
hydroxy;
halo;
C-carboxy substituted with a group selected from the group
20 consisting of:
hydrogen; or,
unsubstituted lower alkyl;
amino; or,
-NR¹¹R¹²;
25 unsubstituted lower alkyl alkoxy;
lower alkyl alkoxy substituted with one or more halo groups;
unsubstituted aryloxy;
aryloxy substituted with one or more groups independently selected from the group consisting of:
30 unsubstituted lower alkyl;

240/090
PATENT

lower alkyl substituted with one or more halo groups;
hydroxy;
unsubstituted lower alkyl alkoxy;
halo;
5 amino; or,
-NR¹¹R¹²;

S-sulfonamido wherein R¹¹ and R¹² are independently selected from
the group consisting of hydrogen and unsubstituted lower alkyl;
unsubstituted aryl;

10 aryl substituted with one or more groups independently selected
from the group consisting of:

halo;
unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
15 unsubstituted lower alkyl alkoxy;
amino; or,
-NR¹¹R¹²;

unsubstituted heteroaryl;

heteroaryl substituted with one or more groups independently
20 selected from the group consisting of:

unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
hydroxy;
25 halo;
amino; or,
-NR¹¹R¹²;

unsubstituted heteroalicyclic;

heteroalicyclic substituted with one or more groups independently
30 selected from the group consisting of:

240/090
PATENT

halo;

hydroxy;

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;

5 unsubstituted lower alkyl alkoxy;

amino; or,

 $R^{11}R^{12}$;

unsubstituted lower alkyl O-carboxy;

10 C-amido wherein R^{11} and R^{12} are independently selected from the
group consisting of hydrogen, unsubstituted lower alkyl and
unsubstituted aryl; and,

15 N-amido wherein R^{11} and R^{12} are independently selected from the
group consisting of hydrogen, unsubstituted lower alkyl and
unsubstituted aryl.

5. The compound of claim 3 wherein wherein R^3 , R^4 , R^5 and
 R^6 are selected from the group consisting of:

hydrogen;

halo;

20 unsubstituted lower alkyl;

lower alkyl substituted with one or more groups selected from the
group consisting of:

hydroxy;

halo;

25 C-carboxy substituted with a group selected from the group
consisting of:

hydrogen; or,

unsubstituted lower alkyl;

amino; or,

30 $-NR^{11}R^{12}$;

240/090
PATENT

unsubstituted lower alkyl alkoxy;
lower alkyl alkoxy substituted with one or more halo groups;
unsubstituted aryloxy;
aryloxy substituted with one or more groups independently selected
5 from the group consisting of:

unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
hydroxy;
unsubstituted lower alkyl alkoxy;
10 halo;
amino; or,
-NR¹¹R¹²;

S-sulfonamido wherein R¹¹ and R¹² are independently selected from
the group consisting of hydrogen and unsubstituted lower alkyl;
15 unsubstituted aryl;
aryl substituted with one or more groups independently selected
from the group consisting of:

halo;
unsubstituted lower alkyl;
20 lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
amino; or,
-NR¹¹R¹²;

unsubstituted heteroaryl;

25 heteroaryl substituted with one or more groups independently
selected from the group consisting of:

unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
30 hydroxy;

240/090
PATENT

halo;
amino; or,
-NR¹¹R¹²;

unsubstituted heteroalicyclic;

- 5 heteroalicyclic substituted with one or more groups independently selected from the group consisting of:

halo;
hydroxy;

unsubstituted lower alkyl;

- 10 lower alkyl substituted with one or more halo groups;

unsubstituted lower alkyl alkoxy;

amino; or,

R¹¹R¹²;

unsubstituted lower alkyl O-carboxy;

- 15 C-amido wherein R¹¹ and R¹² are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl; and,

N-amido wherein R¹¹ and R¹² are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and

- 20 unsubstituted aryl.

6. The compound of claim 1, wherein:

R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are hydrogen;

R⁸ and R¹⁰ are methyl; and,

- 25 R⁹ is -(CH₂)(CH₂)C(=O)OH.

7. A pharmaceutical composition, comprising:

said compound of claim 6; and,

a physiologically acceptable carrier or excipient.

240/090
PATENT

8. The compound of claim 1, wherein:

R¹, R² and R⁷ are hydrogen;

R³, R⁴, R⁵ and R⁶ are independently selected from the group consisting of:

5 hydrogen;

hydroxy;

halo;

unsubstituted lower alkyl;

lower alkyl substituted with a carboxylic acid;

10 unsubstituted lower alkoxy;

carboxylic acid;

unsubstituted aryl;

aryl substituted with one or more unsubstituted lower alkyl alkoxy; or,

15 morpholino;

R⁸ is selected from the group consisting of hydrogen and unsubstituted lower alkyl;

R⁹ is $-(CH_2)(CH_2)C(=O)OH$; and,

R¹⁰ is unsubstituted lower alkyl.

20

9. The compound of claim 2 wherein R⁷ is selected from the group consisting of:

hydrogen,

unsubstituted lower alkyl, and,

25 lower alkyl substituted with a group selected from the group consisting of:

unsubstituted cycloalkyl,

unsubstituted aryl, and,

aryl substituted with a group selected from hydroxy,

30 unsubstituted lower alkyl alkoxy and halo.

240/090
PATENT

10. The compound of claim 2 wherein Z is selected from the group consisting of:

-C(=O)NR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently selected from the group consisting of:

- 5 hydrogen,
 unsubstituted lower alkyl,
 lower alkyl substituted with a group selected from the group
 consisting of amino and -NR¹¹R¹²,
 unsubstituted aryl,
10 aryl substituted with one or more groups selected from the
 group consisting of halo, hydroxy, unsubstituted lower alkyl
 alkoxy and trihalomethyl,
 unsubstituted heteroaryl,
 unsubstituted heteroalicyclic, and,
15 combined, a five-member or a six-member unsubstituted
 heteroalicyclic, and,
 -NR¹¹R¹², wherein,
 R¹¹ and R¹² are independently selected from the group consisting of
 unsubstituted lower alkyl and, combined, a five-member or a six-
20 member unsubstituted heteroalicyclic ring.

11. The compound of claim 1 wherein:

R⁷ is selected from the group consisting of unsubstituted lower alkyl,

- 25 lower alkyl substituted with one or more groups selected from the
 group consisting of:

- unsubstituted cycloalkyl,
 unsubstituted aryl,
 aryl substituted with one or more groups independently
30 selected from the group consisting of halo and unsubstituted

240/090
PATENT

lower alkyl alkoxy and unsubstituted lower alkyl
carboxyalkyl, and,

Z is selected from the group consisting of unsubstituted C-
carboxy and unsubstituted lower alkyl C-carboxy.

5

12. The compound of claim 1 wherein:

R^3 , R^4 , R^5 , and R^6 are independently selected from the group
consisting of

hydrogen,

10 halo,

unsubstituted lower alkyl,

lower alkyl substituted with one or more hydroxy groups,

unsubstituted lower alkoxy,

unsubstituted aryl,

15 aryl substituted with one or more unsubstituted lower alkoxy
groups, and,

$S(O)_2NR^{11}R^{12}$,

R^5 is hydrogen,

R^6 is $-NR^{11}R^{12}$, and,

20 R^{11} and R^{12} are independently selected from the group consisting
of hydrogen, unsubstituted lower alkyl and, combined, a five-
member or a six-member unsubstituted heterocyclic ring.25 13. A method for the modulation of the catalytic activity
of a protein kinase comprising contacting said protein kinase
with a compound, salt or prodrug of claim 1.30 14. The method of claim 13 wherein said protein kinase is
selected from the group consisting of a receptor tyrosine kinase,
a non-receptor tyrosine kinase and a serine-threonine kinase.

240/090
PATENT

15. A pharmaceutical composition, comprising:
a compound, salt or prodrug of claim 1; and,
a physiologically acceptable carrier or excipient.

5 16. A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a compound, salt or prodrug of claim 1 to said organism.

10 17. The method of claim 16 comprising administering therapeutically effective amount of 3-[2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid to said organism.

15 18. The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

20 19. The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

25 20. The method of claim 16 wherein said protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck
30 cancer, melanoma, ovarian cancer, prostate cancer, breast

240/090
PATENT

cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

21. The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

10
22. The method of claim 16 wherein said organism is a human.

23. A compound from the group consisting of:

- 15 3-[5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid
- 3-[5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid
- 20 3-[5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-yl]-propionic acid
- 3-[4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid
- 3-[2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid
- 25 3-[5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid
- 3-[5-(5-Iodo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid
- 3-[4-Methyl-5-(4-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid
- 30

240/090
PATENT

3-[4-Methyl-5-(5-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid

3-[5-(5,6-Dimethoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid

5 3-[5-(6-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid

3-[4-(2-Carboxyethyl)-3-methyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid methyl ester

10 3-[4-(2-Carboxy-ethyl)-3-methyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid

3-[4-Methyl-5-(2-oxo-5-sulfamoyl-1,2-dihydroindol-3-ylidene-methyl)-1H-pyrrol-3-yl]-propionic acid

3-[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid

15 3-{3-[4-(2-Carboxy-ethyl)-3-methyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indol-5-yl}-propionic acid

3-[5-(5-Ethyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid

20 3-[5-(5-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid

3-[5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-yl]-propionic acid

3-[5-(5-Iodo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-yl]-propionic acid

25 3-[2,4-Dimethyl-5-(4-methyl-2-oxo-1,2-dihydroindol-3-ylidene-methyl)-1H-pyrrol-3-yl]-propionic acid

3-[2,4-Dimethyl-5-(5-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid

30 3-[5-(6-Hydroxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-yl]-propionic acid

240/090
PATENT

3-[5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-yl]-propionic acid

3-[5-(6-Hydroxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid

5 3-[5-(6-Hydroxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid 3,5-dimethoxy-benzyl ester

3-{5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid

10 3-[5-(6-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1H-pyrrol-3-yl]-propionic acid

3-{5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-4-methyl-1H-pyrrol-3-yl}-propionic acid

3-{5-[6-(3-Ethoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid

15 3-{5-[6-(3-Ethoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-4-methyl-1H-pyrrol-3-yl}-propionic acid

3-[2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid

20 3-[4-Methyl-5-(2-oxo-6-phenyl-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid

3-{5-[6-(4-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-4-methyl-1H-pyrrol-3-yl}-propionic acid

3-{5-[6-(4-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid

25 3-{5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-4-methyl-1H-pyrrol-3-yl}-propionic acid

3-{5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-propionic acid

30 3-[2,4-Dimethyl-5-(6-morpholin-4-yl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid

240/090
PATENT

3- [5- (5-Chloro-4-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl) -2,4-dimethyl-1H-pyrrol-3-yl] -propionic acid

3- [5- (5-Chloro-4-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl) -4-methyl-1H-pyrrol-3-yl] -propionic acid

5 3- [2,4-Dimethyl-5- (2-oxo-1,2-dihydroindol-3-ylidenemethyl) -1H-pyrrol-3-yl] -propionic acid, sodium salt

24. A compound selected from the group consisting of:

- 3- [3,5-Dimethyl-4- (3-morpholin-4-ylpropyl) -1H-pyrrol-2-ylmethylene] -1,3-dihydroindol-2-one
- 10 5-Bromo-3- [3,5-dimethyl-4- (3-morpholin-4-ylpropyl) -1H-pyrrol-2-ylmethylene] -1,3-dihydroindol-2-one
- 3- [3,5-Dimethyl-4- (3-morpholin-4-ylpropyl) -1H-pyrrol-2-ylmethylene] -6-phenyl-1,3-dihydroindol-2-one
- 15 3- [3,5-Dimethyl-4- (3-morpholin-4-ylpropyl) -1H-pyrrol-2-ylmethylene] -6- (2-methoxyphenyl) -1,3-dihydroindol-2-one
- 3- [3,5-Dimethyl-4- (3-morpholin-4-ylpropyl) -1H-pyrrol-2-ylmethylene] -6- (3-methoxyphenyl) -1,3-dihydroindol-2-one
- 3- [3,5-Dimethyl-4- (3-morpholin-4-ylpropyl) -1H-pyrrol-2-ylmethylene] -6- (4-methoxyphenyl) -1,3-dihydroindol-2-one
- 20 3- [4- (3-Dimethylaminopropyl) -3,5-dimethyl-1H-pyrrol-2-ylmethylene] -1,3-dihydroindol-2-one
- 5-Bromo-3- [4- (3-dimethylaminopropyl) -3,5-dimethyl-1H-pyrrol-2-ylmethylene] -1,3-dihydroindol-2-one
- 25 3- [4- (3-Dimethylaminopropyl) -3,5-dimethyl-1H-pyrrol-2-ylmethylene] -6-phenyl-1,3-dihydroindol-2-one
- 3- [4- (3-Dimethylaminopropyl) -3,5-dimethyl-1H-pyrrol-2-ylmethylene] -6- (2-methoxyphenyl) -1,3-dihydroindol-2-one
- 3- [4- (3-Dimethylaminopropyl) -3,5-dimethyl-1H-pyrrol-2-ylmethylene] -6- (3-methoxyphenyl) -1,3-dihydroindol-2-one
- 30

240/090
PATENT

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-(4-methoxyphenyl)-1,3-dihydroindol-2-one

5-Chloro-3-[4-(3-dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

5 6-Chloro-3-[4-(3-dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-methoxy-1,3-dihydroindol-2-one

10 3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-methoxy-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-methyl-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-4-methyl-1,3-dihydroindol-2-one

15 3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-4-(2-hydroxyethyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid amide

20 3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid isopropylamide

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-(morpholine-4-sulfonyl)-1,3-dihydroindol-2-one

25 3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide.